Patents Assigned to Wyeth
  • 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]-naphthalenyl derivatives with antipsychotic activity
    Patent number: 6541502
    Abstract: Compounds of the Formula (I): are useful in the treatment of disorders associated with dopamine dysregulation.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: April 1, 2003
    Assignee: Wyeth
    Inventors: Richard E. Mewshaw, Rulin Zhao
  • Monoclonal antibodies obtained using rapamycin position 27 conjugates as an immunogen
    Patent number: 6541612
    Abstract: Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin or a derivative thereof, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides monoclonal antibodies specific for rapamycin or a ring opened derivative of rapamycin.
    Type: Grant
    Filed: February 2, 2001
    Date of Patent: April 1, 2003
    Assignee: Wyeth
    Inventors: Katherine L. Molnar-Kimber, Craig E. Caufield, Timothy D. Ocain, Amadeo A. Failli
  • 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]-naphthalenyl derivatives with antipsychotic activity
    Patent number: 6541501
    Abstract: Compounds of the Formula (I): are useful in the treatment of disorders associated with brain dopamine dysregulation.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: April 1, 2003
    Assignee: Wyeth
    Inventors: Richard E. Mewshaw, Rulin Zhao
  • Method of treating inflammatory bowel disease using a topical formulation of IL-11
    Patent number: 6540993
    Abstract: Provided by the present invention are topical formulations of Interleukin-11 and methods for treating a variety of disorders, including inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis, indeterminate colitis, and infectious colitis), mucositis (e.g., oral mucositis, gastrointestinal mucositis, nasal mucositis, and proctitis), necrotizing enterocolitis, inflammatory skin disorders (e.g., psoriasis, atopic dermatitis, and contact hypersensitivity), aphthous ulcers, pharyngitis, esophagitis, peptic ulcers, gingivitis, periodontitis, and ocular diseases (e.g., conjunctivitis, retinitis, and uveitis).
    Type: Grant
    Filed: September 15, 2000
    Date of Patent: April 1, 2003
    Assignee: Wyeth
    Inventors: Nicholas W. Warne, Camille L. Bedrosian, James C. Keith, Jr., Ullrich S. Schwerschlag, Paul F. Schendel
  • 2,3,4,4a-Tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives
    Publication number: 20030060468
    Abstract: This invention provides compounds of formula I, 1
    Type: Application
    Filed: September 16, 2002
    Publication date: March 27, 2003
    Applicant: Wyeth
    Inventors: Sharon Joy Rosenzweig-Lipson, Annmarie Louise Sabb, Gregory Scott Welmaker, James Albert Nelson
  • Heterocyclic &bgr;3 adrenergic receptor agonists
    Patent number: 6537994
    Abstract: This invention provides compounds of Formula I having the structure wherein, U, V, and W are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: March 25, 2003
    Assignee: Wyeth
    Inventors: Mark Anthony Ashwell, William Ronald Solvibile
  • Reversal of multidrug resistance in human colon carcinoma cells
    Patent number: 6537964
    Abstract: The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: March 25, 2003
    Assignee: Wyeth Holdings Corporation
    Inventors: Haiyin He, Lee Martin Greenberger
  • Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
    Patent number: 6537971
    Abstract: This invention provides tissue selective estrogens of formula I having the structure wherein: R1 and R2 are independently, hydrogen, alkyl chain of 1-6 carbon atoms, benzyl, acyl of 2-7 carbon atoms, benzoyl, X is hydrogen, alkyl of 1-6 carbon atoms, CN, halogen, trifluoromethyl, or thioalkyl of 1-6 carbon atoms; n=1-3; with the proviso that at least one of R1 or R2 are not hydrogen, alkyl chain of 1-6 carbon atoms, benzyl, acyl of 2-7 carbon atoms, or benzoyl; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 1, 2002
    Date of Patent: March 25, 2003
    Assignee: Wyeth
    Inventors: Chris P. Miller, Michael D. Collini, Bach D. Tran, Anita Wai-Yin Chan, Arkadiy Z. Rubezhov
  • Novel pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
    Publication number: 20030055046
    Abstract: The present invention provides novel tricyclic pyridyl carboxamides as well as methods and pharmaceutical compositions utilizing them compounds for the treatment and/or prevention and/or suppression of disorders which may be remedied or alleviated by oxytocin antagonist activity, including prevention and/or suppression of preterm labor, suppression of labor at term prior to caesarean delivery, and for the treatment of dysmenorrhea. These compounds are also useful in enhancing fertility rates, enhancing survival rates and synchronizing estrus in farm animals; and may be useful in the prevention and treatment of disfunctions of the oxytocin system in the central nervous system including obsessive compulsive disorder (OCD) and neuropsychiatric disorders.
    Type: Application
    Filed: April 10, 2002
    Publication date: March 20, 2003
    Applicant: Wyeth
    Inventors: Amedeo Arturo Failli, William Jennings Sanders, Eugene John Trybulski
  • Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
    Publication number: 20030055047
    Abstract: This invention provides novel substituted tricyclic pyridyl carboxamides which act as oxytocin receptor competitive antagonists, as well as methods of their manufacture, pharmaceutical compositions and methods of their use in treatment, inhibition, suppression or prevention of preterm labor, dysmenorrhea, endometritis, suppression of labor at term prior to caesarean delivery, and to facilitate antinatal transport to a medical facility. These compounds are also useful in enhancing fertility rates, enhancing survival rates and synchronizing estrus in farm animals; and may be useful in the prevention and treatment of disfunctions of the oxytocin system in the central nervous system including obsessive compulsive disorder (OCD) and neuropsychiatric disorders.
    Type: Application
    Filed: April 10, 2002
    Publication date: March 20, 2003
    Applicant: Wyeth
    Inventors: Amedeo Arturo Failli, Jay Scott Shumsky, Thomas Joseph Caggiano, Joseph Peter Sabatucci, Kevin Anthony Memoli, Eugene John Trybulski
  • Combination of a PTPase inhibitor and an ACE inhibitor
    Publication number: 20030055058
    Abstract: This invention relates to pharmaceutical compositions and methods of treatment utilizing a PTPase (protein-tyrosine phosphatase) inhibitors and an angiotensin converting enzyme (ACE) inhibitor to lower the risk of cardiovascular disease and cardiovascular events in a mammal experiencing or subject to type II diabetes in mammals experiencing or subject to type II diabetes (non-insulin-dependent diabetes mellitus), preferably in human type II diabetics, or Syndrome X.
    Type: Application
    Filed: June 6, 2002
    Publication date: March 20, 2003
    Applicant: Wyeth
    Inventors: Danyi Zhang, Xu Meng, Alvin Norio Kotake
  • Azolidines as beta-3 adrenergic receptor agonists
    Publication number: 20030055079
    Abstract: This invention provides compounds of Formula I having the structure 1
    Type: Application
    Filed: August 23, 2002
    Publication date: March 20, 2003
    Applicant: Wyeth
    Inventors: Michael Sotirios Malamas, Elwood Eugene Largis, Iwan Gunawan, Zenan Li
  • Antineoplastic combinations
    Publication number: 20030050222
    Abstract: This invention provides the use of a combination of CCI-779 and EKB-569 in the treatment of neoplasms.
    Type: Application
    Filed: August 6, 2002
    Publication date: March 13, 2003
    Applicant: Wyeth
    Inventors: Sridhar K. Rabindran, James J. Gibbons
  • Cyclic regimens utilizing indoline derivatives
    Publication number: 20030050288
    Abstract: This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: 1
    Type: Application
    Filed: May 22, 2002
    Publication date: March 13, 2003
    Applicant: WYETH
    Inventors: Gary S. Grubb, Andrew Fensome, Lori L. Miller, John W. Ullrich, Reinhold H.W. Bender, Puwen Zhang, Jay E. Wrobel, James P. Edwards, Todd K. Jones, Christopher M. Tegley, Lin Zhi
  • 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
    Publication number: 20030045560
    Abstract: This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: 1
    Type: Application
    Filed: June 13, 2002
    Publication date: March 6, 2003
    Applicant: Wyeth
    Inventors: Thomas Joseph Commons, Susan Christman Croce, Richard Page Woodworth, Eugene John Trybulski, Hassan Mohmoud Elokdah, David LeRoy Crandall
  • Antipsychotic aminomethyl derivatives of 1,3,7,8-tetrahydro-6,9-dioxa-1,3-diaza-cyclopenta[a]-naphthalen-2-one
    Publication number: 20030045526
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: April 23, 2002
    Publication date: March 6, 2003
    Applicant: Wyeth
    Inventor: Gary P. Stack
  • Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline
    Publication number: 20030045542
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: August 27, 2002
    Publication date: March 6, 2003
    Applicant: Wyeth
    Inventors: Megan Tran, Gary P. Stack
  • Combination regimens using progesterone receptor modulators
    Publication number: 20030045511
    Abstract: This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: 1
    Type: Application
    Filed: May 9, 2002
    Publication date: March 6, 2003
    Applicant: WYETH
    Inventors: Gary S. Grubb, Puwen Zhang, Eugene A. Terefenko, Andrew Fensome, Jay E. Wrobel, Horace Fletcher, James P. Edwards, Todd K. Jones, Christopher M. Tegley, Lin Zhi
  • 2-(AMINOMETHYL)-TETRAHYDRO-9-OXA-1,3-DIAZA-CYCLOPENTA[A]-NAPHTHALENYL DERIVATIVES WITH ANTIPSYCHOTIC ACTIVITY
    Publication number: 20030037701
    Abstract: Compounds of the Formula (I): 1
    Type: Application
    Filed: July 18, 2002
    Publication date: February 27, 2003
    Applicant: wyeth
    Inventors: Richard E. Mewshaw, Rulin Zhao
  • B-ring estratrienes
    Patent number: 6525039
    Abstract: This invention provides 3&bgr;-hydroxy-5,7,9-estratriene-17-one and a pharmaceutically acceptable salt of its 3-sulfate ester, which is useful as an estrogen.
    Type: Grant
    Filed: April 21, 1998
    Date of Patent: February 25, 2003
    Assignee: Wyeth
    Inventors: Syed M. Shah, Panolil Raveendranath, Michael Z. Kagan